Experienced in Idiopathic Neutropenia

Dr. Jasmine M. Zain

Hematology | Oncology | Hematology Oncology
Memorial Hematology Lymphoma Group
530 E 74th St, 
New York, NY 
Offers Telehealth
34 Years of Experience
Experienced in Idiopathic Neutropenia
Memorial Hematology Lymphoma Group
530 E 74th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jasmine Zain is a Hematologist and an Oncologist in New York, New York. Dr. Zain has been practicing medicine for over 34 years and is rated as an Experienced provider by MediFind in the treatment of Idiopathic Neutropenia. Her top areas of expertise are T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 120 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Hematology Oncology
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MEMORIAL HEMATOLOGY LYMPHOMA GROUP
530 E 74th St, New York, NY 10021
Other Locations
MEMORIAL HEMATOLOGY LYMPHOMA GROUP
1275 York Ave, New York, NY 10065
MSK MONMOUTH
480 Red Hill Rd, Middletown, NJ 07748

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Other, Biological
Study Drug: MEDI-570
Study Phase: Phase 1
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
Enrollment Status: Completed
Publish Date: November 26, 2025
Intervention Type: Biological, Drug
Study Drugs: Blinatumomab, Lenalidomide
Study Phase: Phase 1
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination With Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma
A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination With Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 16, 2025
Intervention Type: Procedure, Biological
Study Drugs: Magrolimab, Mogamulizumab
Study Phase: Phase 1/Phase 2
Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Mature T-Cell Non-Hodgkin Lymphoma: the aTAC BEAM Regimen
Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Mature T-Cell Non-Hodgkin Lymphoma: the aTAC BEAM Regimen
Enrollment Status: Completed
Publish Date: March 20, 2025
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Yttrium Y 90 Basiliximab, Carmustine, Etoposide, Cytarabine, Melphalan
Study Phase: Phase 1
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Enrollment Status: Completed
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: Duvelisib
Study Phase: Phase 2
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: SEA-TGT, Pembrolizumab
Study Phase: Phase 1
Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma
Nivolumab With Standard of Care Chemotherapy for the First Line Treatment of Peripheral T Cell Lymphoma
Enrollment Status: Completed
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: Nivolumab+EPOCH
Study Phase: Phase 1/Phase 2
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL
Enrollment Status: Active_not_recruiting
Publish Date: April 10, 2024
Intervention Type: Other, Drug
Study Drugs: Romidepsin, Lenalidomide
Study Phase: Phase 2
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
Enrollment Status: Completed
Publish Date: December 13, 2023
Intervention Type: Drug, Other, Procedure
Study Drugs: Cyclophosphamide, Doxorubicin, Etoposide, Lenalidomide, Prednisone, Vincristine
Study Phase: Phase 1/Phase 2
A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma
A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma
Enrollment Status: Suspended
Publish Date: November 13, 2023
Intervention Type: Other, Biological
Study Drug: MT-101
Study Phase: Phase 1/Phase 2
A Phase 2 Study of Venetoclax and Romidepsin With Safety Lead-In for Treatment of Relapsed/Refractory Mature T-Cell Lymphomas
A Phase 2 Study of Venetoclax and Romidepsin With Safety Lead-In for Treatment of Relapsed/Refractory Mature T-Cell Lymphomas
Enrollment Status: Completed
Publish Date: October 19, 2023
Intervention Type: Other, Drug
Study Drugs: Romidepsin, Venetoclax
Study Phase: Phase 2
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL
A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL
Enrollment Status: Completed
Publish Date: November 20, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Trial of Brentuximab Vedotin Plus Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-Cell Lymphomas
A Phase 1 Trial of Brentuximab Vedotin Plus Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-Cell Lymphomas
Enrollment Status: Withdrawn
Publish Date: April 30, 2019
Intervention Type: Drug, Other
Study Phase: Phase 1
View 14 Less Clinical Trials

122 Total Publications

T-Cell Receptor Clonotypes and Aggressive Subtypes in Cutaneous T-Cell Lymphoma.
T-Cell Receptor Clonotypes and Aggressive Subtypes in Cutaneous T-Cell Lymphoma.
Journal: JAMA dermatology
Published: October 22, 2025
Similar Doctors
Distinguished in Idiopathic Neutropenia
Dr. Khalid O. Dar
Hematology Oncology | Oncology | Hematology
Distinguished in Idiopathic Neutropenia
Dr. Khalid O. Dar
Hematology Oncology | Oncology | Hematology

Icahn School Of Medicine At Mount Sinai

1000 10th Ave, 
New York, NY 
 (1.9 miles away)
212-523-5559
Languages Spoken:
English
See accepted insurances

Khalid Dar is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Dar is rated as an Advanced provider by MediFind in the treatment of Idiopathic Neutropenia. His top areas of expertise are Idiopathic Neutropenia, Thrombocytopenia, Iron Deficiency Anemia, Pulmonary Embolism, and Bone Marrow Aspiration.

Distinguished in Idiopathic Neutropenia
Dr. Mathew Lonberg
Hematology | Oncology
Distinguished in Idiopathic Neutropenia
Dr. Mathew Lonberg
Hematology | Oncology

White Plains Medical Diagnostic Services, PC

41 E Post Rd, 
White Plains, NY 
 (20.2 miles away)
914-681-1201
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mathew Lonberg is a Hematologist and an Oncologist in White Plains, New York. Dr. Lonberg is rated as a Distinguished provider by MediFind in the treatment of Idiopathic Neutropenia. His top areas of expertise are Paget Disease of the Breast, Idiopathic Neutropenia, Chronic Lymphocytic Leukemia (CLL), and Schnitzler Syndrome.

Advanced in Idiopathic Neutropenia
Dr. Johnson M. Liu
Hematology Oncology | Hematology | Oncology
Advanced in Idiopathic Neutropenia
Dr. Johnson M. Liu
Hematology Oncology | Hematology | Oncology

Icahn School Of Medicine At Mount Sinai

1 Gustave L Levy Pl, 
New York, NY 
 (1.6 miles away)
212-731-7650
Languages Spoken:
English
See accepted insurances

Johnson Liu is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Liu is rated as an Advanced provider by MediFind in the treatment of Idiopathic Neutropenia. His top areas of expertise are Idiopathic Neutropenia, Thrombocytopenia, Iron Deficiency Anemia, Shwartzman Phenomenon, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zain's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 8 Distinguished Conditions
View All 17 Advanced Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile